| Affiliation: | 1.Servicio Oncología Radioterápica- ERESA,Hospital General Universitario,Valencia,Spain;2.S.Oncología Radioterápica,Institut Catala d’Oncologia,Hospitalet,Spain;3.S.Oncología Radioterápica,Hospital Universitario Doce de Octubre,Madrid,Spain;4.S.Oncología Radioterápica,Hospital Universitario de la Princesa,Madrid,Spain;5.S.Oncología Radioterápica,Institut Catala d’Oncologia,Badalona,Spain;6.Escuela Universitaria Politécnica de La Almunia,Universidad de Zaragoza,Zaragoza,Spain;7.S.Oncología Radioterápica,Hospital Universitari Sant Joan de Reus,Reus,Spain;8.S.Oncología Radioterápica,Fundación Instituto Valenciano de Oncología,Valencia,Spain;9.S.Oncología Radioterápica,Hospital Universitario Gregorio Mara?on,Madrid,Spain;10.S.Oncología Radioterápica,Hospital Clínico Universitario de Santiago,Santiago de Compostela,Spain;11.S.Oncología Radioterápica,Fundación Instituto Valenciano de Oncología,Valencia,Spain;12.S.Oncología Radioterápica,Hospital Universitario Ramón y Cajal,Madrid,Spain;13.S.Oncología Radioterápica,Hospital Infanta Cristina,Badajoz,Spain;14.Departamento de Métodos Estadísticos,Universidad de Zaragoza,Zaragoza,Spain |
| Abstract: | BackgroundNomograms were established to predict biochemical recurrence (BCR) after radiotherapy (RT) with a low weight of the characteristic variables of RT and androgen deprivation therapy (ADT). Our aim is to provide a new stratified tool for predicting BCR at 4 and 7 years in patients treated using RT with radical intent.Materials and methodsA retrospective, nonrandomized analysis was performed on 5044 prostate cancer (PCa) patients with median age 70 years, who received RT—with or without ADT—between November 1992 and May 2007. Median follow-up was 5.5 years. BCR was defined as a rise in serum prostate-specific antigen (PSA) of 2 ng/ml over the post-treatment PSA nadir. Univariate association between predictor variables and BCR was assessed by the log-rank test, and three linked nomograms were created for multivariate prognosis of BCR-free survival. Each nomogram corresponds to a category of the Gleason score—either 6,7, or 8–10—and all of them were created from a single proportional hazards regression model stratified also by months of ADT (0, 1–6, 7–12, 13–24, 25–36, 36–60). The performance of this model was analyzed by calibration, discrimination, and clinical utility.ResultsInitial PSA, clinical stage, and RT dose were significant variables ( p? ConclusionFor each Gleason score category, the nomogram provides information on the benefit of adding ADT to a specific RT dose. |
